Recombinetics Announces Major Advancements in the Development of a Novel Swine Model of Neurofibromatosis Type 1
Recombinetics announced the development of the first-of-their-kind gene-edited swine models for Neurofibromatosis Type 1 (NF1). Partially funded by the Children’s Tumor Foundation, and in collaboration with the University of Minnesota, these models are for use in preclinical safety and efficacy testing of therapeutics for this debilitating genetic disease affecting 1 [...]
Gene Editing Market Outlook: Biotech & Pharma to be the Leading End-User
https://gminsights.wordpress.com/2017/02/09/gene-editing-market/